Tarsus Pharmaceuticals (TARS) has the first and only approved treatment for Demodex Blepharitis, Xdemvy. The FDA approved Xdemvy for treatment of Demodex Blepharitis in July 2023. CEO of Tarsus Pharmaceuticals Bobby Azamian, MD, PhD joins Oliver Renick to discuss the biopharmaceutical company. The company focuses on novel therapies or ophthalmic conditions. Tune in to find out more about the stock market today.
Morning Trade Live
09 Jan 2024
SHARE
Morning Trade Live
29 Feb 2024
The Watch List
02 Feb 2024
Morning Trade Live
07 Mar 2024
The Watch List
05 Mar 2024
Market On Close
30 Jan 2024
Market On Close
06 Mar 2024